Our Pricing

Wegovy Semaglutide - Private Prescription, No GP Referral

Published on: June 03, 2026

Seeking a wegovy semaglutide private prescription uk without the NHS waiting list? At Cured Pharmacy, you can access genuine UK-licensed Wegovy injections with transparent pricing, a free online consultation completed in under 3 minutes, and discreet next-day delivery—no GP referral required.

How Wegovy Semaglutide Works for Weight Loss

Wegovy contains semaglutide, a glucagon-like peptide-1 (GLP-1) receptor agonist licensed by the MHRA for chronic weight management in adults with a BMI of 30 kg/m² or greater, or 27 kg/m² with at least one weight-related comorbidity [1]. Semaglutide mimics the action of GLP-1, a naturally occurring hormone that regulates appetite and food intake by acting on receptors in the brain that control hunger signals.

In the landmark STEP 1 clinical trial, participants using semaglutide 2.4 mg weekly achieved an average body weight reduction of 14.9% over 68 weeks, compared to 2.4% with placebo [1]. Wegovy works by slowing gastric emptying, increasing feelings of fullness, and reducing overall caloric intake—mechanisms that support sustainable weight loss when combined with a reduced-calorie diet and increased physical activity [2].

Wegovy Private Prescription UK: No GP Referral Needed

Unlike NHS pathways that often require lengthy GP referrals and tier 3 weight management programme completion, accessing a wegovy semaglutide private prescription uk through Cured Pharmacy is straightforward. Our UK-registered prescribers conduct a comprehensive online clinical assessment that typically takes under 3 minutes to complete, evaluating your medical history, current medications, and suitability for semaglutide treatment.

Once approved, your prescription is issued by a GMC-registered clinician and dispensed by our GPhC-registered pharmacy (registration number 9012511) under the supervision of Superintendent Pharmacist Tarun Kumar (GPhC 2233073). This private prescription route allows eligible patients to begin treatment without navigating NHS waiting lists, which can extend several months in many UK regions.

Who Can Get a Private Wegovy Prescription?

Wegovy is licensed for adults with a BMI of 30 kg/m² or above, or 27 kg/m² or above with at least one weight-related health condition such as type 2 diabetes, hypertension, or obstructive sleep apnoea [1]. During your online consultation, our prescribers will assess your eligibility based on MHRA licensing criteria and clinical guidelines. Wegovy is not suitable for everyone—patients with a personal or family history of medullary thyroid carcinoma or multiple endocrine neoplasia syndrome type 2 should not use semaglutide [3].

Wegovy Dosing Schedule and What to Expect

Wegovy follows a gradual dose escalation schedule designed to minimise gastrointestinal side effects while optimising efficacy. Treatment begins with a 0.25 mg subcutaneous injection once weekly for four weeks, then increases monthly through 0.5 mg, 1 mg, and 1.7 mg doses, reaching the maintenance dose of 2.4 mg by week 17 [3]. This titration approach allows your body to adapt to semaglutide's effects on gastric emptying and appetite regulation.

Most patients begin noticing reduced appetite and smaller portion sizes within the first few weeks of treatment. Clinical trial data shows that weight loss typically accelerates during the dose escalation phase, with maximum effects observed after reaching the 2.4 mg maintenance dose [1]. Your UK prescriber may adjust the titration schedule based on your individual tolerance and response, and regular follow-up consultations ensure treatment remains safe and effective throughout your weight loss journey.

How Long Should You Use Wegovy?

Wegovy is intended for long-term weight management rather than short-term use. Clinical guidelines recommend evaluating treatment response after 16 weeks at the maintenance dose—if you have not achieved at least 5% body weight loss by this point, discontinuation should be considered [3]. Many patients continue treatment for 12 months or longer to achieve and maintain clinically significant weight loss, with ongoing prescriber oversight to monitor efficacy and safety.

Wegovy vs Mounjaro: Comparing Semaglutide and Tirzepatide

Both Wegovy and Mounjaro are once-weekly injectable medications licensed in the UK for weight management, but they work through different mechanisms. Wegovy contains semaglutide, a GLP-1 receptor agonist, while Mounjaro contains tirzepatide, the first dual GIP/GLP-1 receptor agonist. Tirzepatide activates both glucose-dependent insulinotropic polypeptide (GIP) and GLP-1 receptors, potentially producing greater weight loss effects in clinical trials [4].

In head-to-head comparisons, tirzepatide demonstrated superior weight reduction compared to semaglutide. The SURPASS-2 trial showed participants on tirzepatide 15 mg achieved an average 12.4 kg weight loss compared to 6.2 kg with semaglutide 1 mg over 40 weeks [4]. However, Wegovy remains highly effective for many patients and may be preferred based on individual response, tolerability, cost considerations, and prescriber clinical judgement. At Cured Pharmacy, our UK prescribers will discuss both options during your consultation to determine which treatment aligns best with your weight management goals.

Common Side Effects and How to Manage Them

The most frequently reported side effects of Wegovy are gastrointestinal, including nausea, diarrhoea, vomiting, constipation, and abdominal pain. In the STEP trials, nausea occurred in approximately 44% of participants using semaglutide 2.4 mg, though most cases were mild to moderate and diminished over time [1]. These effects result from semaglutide's action on gastric emptying and are typically most pronounced during dose escalation phases.

To minimise gastrointestinal discomfort, eat smaller, more frequent meals rather than large portions, avoid high-fat and heavily spiced foods, and stay well-hydrated throughout the day. Taking your injection on the same day each week and avoiding dose increases if you're experiencing significant side effects can also improve tolerability. Most patients find that nausea resolves within 4-8 weeks as their body adjusts to the medication [2]. If side effects become severe or persistent, contact your prescriber—they may recommend slowing the dose escalation or adjusting your treatment plan.

Serious Side Effects to Watch For

Though rare, serious side effects can occur with semaglutide. Seek immediate medical attention if you experience severe abdominal pain (which may indicate pancreatitis), signs of thyroid tumours such as a lump in the neck or persistent hoarseness, symptoms of gallbladder problems including jaundice or severe upper abdominal pain, or signs of kidney problems such as decreased urination [3]. Semaglutide may also increase heart rate in some patients, and those with a history of cardiovascular conditions should be monitored appropriately by their prescriber.

Wegovy Price UK and Transparent Pharmacy Costs

At Cured Pharmacy, Wegovy is available with transparent upfront pricing—you'll see the exact cost before completing your consultation. Our wegovy semaglutide private prescription uk service includes the medication, clinical assessment by a UK prescriber, and discreet delivery to your address. We guarantee competitive UK pricing with no hidden fees or surprise charges at checkout.

Private prescription costs for weight loss medications can vary significantly across UK pharmacies, and many platforms don't display prices until after you've completed lengthy consultations. At Cured Pharmacy, we believe in transparent pricing so you can make informed decisions about your treatment. Our prices reflect genuine UK-licensed medications dispensed by our GPhC-registered pharmacy, ensuring you receive the same pharmaceutical-grade Wegovy prescribed through NHS or private clinic routes. All weight loss treatments require ongoing prescriber monitoring, and follow-up consultation costs are clearly outlined during your initial assessment.

Scientific References

1. Wilding, J. P. H., Batterham, R. L., Calanna, S., Davies, M., Van Gaal, L. F., Lingvay, I., ... & Kushner, R. F. (2021). Once-Weekly Semaglutide in Adults with Overweight or Obesity. New England Journal of Medicine, 384(11), 989–1002. https://doi.org/10.1056/NEJMoa2032183 [accessed 13 August 2026]
2. Rubino, D., Abrahamsson, N., Davies, M., Hesse, D., Greenway, F. L., Jensen, C., ... & Sjöström, C. D. (2021). Effect of Continued Weekly Subcutaneous Semaglutide vs Placebo on Weight Loss Maintenance in Adults With Overweight or Obesity: The STEP 4 Randomized Clinical Trial. JAMA, 325(14), 1414–1425. https://doi.org/10.1001/jama.2021.3224 [accessed 13 August 2026]
3. Novo Nordisk. (2023). Wegovy 2.4 mg solution for injection in pre-filled pen: Summary of Product Characteristics. Electronic Medicines Compendium. https://www.medicines.org.uk/emc/product/13799 [accessed 13 August 2026]
4. Frías, J. P., Davies, M. J., Rosenstock, J., Pérez Manghi, F. C., Fernández Landó, L., Bergman, B. K., ... & SURPASS-2 Investigators. (2021). Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes. New England Journal of Medicine, 385(6), 503–515. https://doi.org/10.1056/NEJMoa2107519 [accessed 13 August 2026]
5. NHS. (2026). Tirzepatide: a medicine to manage type 2 diabetes and treat obesity. https://www.nhs.uk/medicines/tirzepatide/ Accessed 13 August 2026.
6. NHS. (2026). Overweight and obesity in adults. https://www.nhs.uk/conditions/overweight-and-obesity/ Accessed 13 August 2026.
7. NHS England. (2026). Weight management injections. https://www.england.nhs.uk/ourwork/prevention/obesity/medicines-for-obesity/weight-management-injections/ Accessed 13 August 2026.

Information on this page is for educational purposes only and is not medical advice. All prescription treatments require clinical assessment by a UK-registered prescriber. Always consult a qualified healthcare professional before starting any new medication. Wegovy is a prescription-only medicine licensed for chronic weight management and must be used under medical supervision.